Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (171-180 of 238) with videos related to

Pageof 24
Sort By:
Journal of Clinical Psychopharmacology|April 24, 2013
Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjectsPetra Hoever, Justin Hay, Mandana Rad, et al.
Clinical and Translational Science|July 16, 2024
The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239Christine Huynh, Jasper Dingemanse, Henriette E Meyer Zu Schwabedissen, et al.
British Journal of Clinical Pharmacology|April 11, 2016
Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjectsAndreas Krause, Jasper Dingemanse, Alexandre Mathis, et al.
Basic & Clinical Pharmacology & Toxicology|December 28, 2018
Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT-774312: A novel CRTH2 antagonistMartine Géhin, Dominik Lott, Hervé Farine, et al.
Clinical Pharmacology and Therapeutics|February 16, 2018
Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human StudyClemens Muehlan, Jules Heuberger, Pierre-Eric Juif, et al.
European Journal of Pharmacology|September 27, 2002
Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptorPaul L M van Giersbergen, Carmela Gnerre, Alexander Treiber, et al.
CNS Drugs|March 15, 2014
Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug usersHans G Cruz, Petra Hoever, Bijan Chakraborty, et al.
British Journal of Clinical Pharmacology|April 9, 2015
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjectsPriska Kaufmann, Séverine Niglis, Shirin Bruderer, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 10, 2012
Development and validation of a fully automated online human dried blood spot analysis of bosentan and its metabolites using the Sample Card And Prep DBS SystemNorbert Ganz, Maharajah Singrasa, Laurent Nicolas, et al.
Pharmaceutical Research|December 29, 2016
Modeling the Effect of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod on Subsets of Blood LymphocytesDominik Lott, Andreas Krause, Christian A Seemayer, et al.
Pageof 24

Showing results (171-180 of 238) with videos related to

Sort By:
Pageof 24
Journal of Clinical Psychopharmacology|April 24, 2013
Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjectsPetra Hoever, Justin Hay, Mandana Rad, et al.
Clinical and Translational Science|July 16, 2024
The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239Christine Huynh, Jasper Dingemanse, Henriette E Meyer Zu Schwabedissen, et al.
British Journal of Clinical Pharmacology|April 11, 2016
Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjectsAndreas Krause, Jasper Dingemanse, Alexandre Mathis, et al.
Basic & Clinical Pharmacology & Toxicology|December 28, 2018
Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT-774312: A novel CRTH2 antagonistMartine Géhin, Dominik Lott, Hervé Farine, et al.
Clinical Pharmacology and Therapeutics|February 16, 2018
Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human StudyClemens Muehlan, Jules Heuberger, Pierre-Eric Juif, et al.
European Journal of Pharmacology|September 27, 2002
Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptorPaul L M van Giersbergen, Carmela Gnerre, Alexander Treiber, et al.
CNS Drugs|March 15, 2014
Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug usersHans G Cruz, Petra Hoever, Bijan Chakraborty, et al.
British Journal of Clinical Pharmacology|April 9, 2015
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjectsPriska Kaufmann, Séverine Niglis, Shirin Bruderer, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 10, 2012
Development and validation of a fully automated online human dried blood spot analysis of bosentan and its metabolites using the Sample Card And Prep DBS SystemNorbert Ganz, Maharajah Singrasa, Laurent Nicolas, et al.
Pharmaceutical Research|December 29, 2016
Modeling the Effect of the Selective S1P<sub>1</sub> Receptor Modulator Ponesimod on Subsets of Blood LymphocytesDominik Lott, Andreas Krause, Christian A Seemayer, et al.
Pageof 24